Clinical trials: Adenovirus Disease
HIV Infections
Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response.
- Trial name
- NCT00695877
- Testing
- Ad5.ENVA.48 HIV-1 vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02313077
- Testing
- MVA-BN-filo, Ad26. ZEBOV
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Prostatic Neoplasms, Prostate Cancer
Vector Delivery of the IL-12 Gene in Men With Prostate Cancer
This study is designed to determine the safety of IL-12 gene therapy for patients with recurrence of prostate cancer after radiation therapy and those with or without metastatic disease with a prostate gland intact.
- Trial name
- NCT00406939
- Testing
- IL-12 gene
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
COVID-19
Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults
This is a randomized, double-blind, parallel-controlled, equivalence trial, for evaluation of safety and immunogenicity, and batch-to-batch consistency of a recombinant adenovirus type-5-vectored Covid-19 vaccine Convidecia in…
- Trial name
- NCT05313646
- Testing
- batch 1 of Ad5-nCoV, batch 2 of Ad5-nCoV, batch 3 of Ad5-nCoV
- Where
- China
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Covid19
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- NCT04564716
- Testing
- Gam-COVID-Vac
- Where
- 8 sites in Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
HIV Infections
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several different dose levels.
- Trial name
- NCT00350623
- Testing
- MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02376426
- Testing
- MVA-BN-Filo, Ad26.ZEBOV
- Where
- Kenya
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hemorrhagic Fever, Ebola
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
- Trial name
- NCT02661464
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 16 sites in United States, Burkina Faso and 5 more
- Volunteers
- 677 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Prostatic Neoplasms, Neoplasm Recurrence, Local
Gene Therapy for Prostate Cancer That Returns After Radiation Therapy
The purpose of this research study is to test a new treatment for prostate cancer. We have been exploring the use of cytokine (immune stimulating) gene therapy by directly injecting a virus which produces a cytokine called…
- Trial name
- NCT00110526
- Testing
- Ad.hIL-12
- Sponsor
- Simon Hall
Hyponatremia, SIADH
Tolvaptan for Patients With Acute Neurological Injuries
Hyponatremia occurs frequently in patients with acute brain injury in the days to weeks following injury, and may contribute to adverse outcome.
- Trial name
- NCT02545114
- Testing
- Tolvaptan
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Polderman, Kees, H., MD, PhD
Hepatitis C
Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients
The purpose of this study is to determine whether administration of recombinant IMPs Ad6NSmut and MVA-NSmut (experimental vaccines for hepatitis C) in HCV chronically infected patients in combination with the standard…
- Trial name
- HCV004 (NCT01701336)
- Testing
- Ad6NSmut, MVA-NSmut
- Where
- 2 sites in Italy
- Volunteers
- 9 people
- Sponsor
- ReiThera Srl
CMV, EBV
Cytotoxic T Cells to Prevent Virus Infections
In this study, investigators are trying to see if infusion of "m-CTLs" will prevent or treat cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV) reactivation or infection after cord blood transplant.
- Conditions
- CMV, EBV, Adenovirus Infections
- Trial name
- NCT01923766
- Testing
- Cytotoxic T lymphocytes (CTLs).
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's National Research Institute
HIV Infections
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
The purpose of this study is to determine the safety and efficacy of a VRC DNA/rAd5 vaccine regimen in healthy, circumcised men and male-to-female (MTF) transgender persons who have sex with men.
- Trial name
- NCT00865566
- Testing
- DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine
- Where
- 22 sites in United States
- Volunteers
- 2,504 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Head and Neck Cancer, Melanoma
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors.
- Conditions
- Head and Neck Cancer, Melanoma, Breast Cancer, Bladder Cancer
- Trial name
- YSCH-01 (NCT05180851)
- Testing
- Recombinant L-IFN adenovirus injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Fengxian District Central Hospital
Healthy
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous and homologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02325050
- Testing
- MVA-BN-Filo, Ad26. ZEBOV
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Triple Negative Breast Cancer
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03387085
- Testing
- Aldoxorubicin HCl, N-803, ETBX-011
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer, High Grade
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
This is an expanded access protocol to study the safety and efficacy of CG0070 in Cis and Cis with Ta and/or T1 disease patients who failed both BCG therapy and the BOND protocol (NCT 01438112), or in high grade Ta and T1…
- Conditions
- Bladder Cancer, High Grade, Non Muscle Invasive
- Trial name
- exBOND (NCT02143804)
- Testing
- oncolytic adenovirus expressing GMCSF
- Where
- United States
- Sponsor
- CG Oncology, Inc.
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response.
- Trial name
- NCT04168333
- Testing
- T101 Group
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Marburg Virus Disease
Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
- Trial name
- NCT05817422
- Testing
- cAd3-Marburg vaccine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute